ALDURAZYME Drug Profile

Summary for Tradename: ALDURAZYME

High Confidence Patents:	31
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ALDURAZYME

Recent Clinical Trials for ALDURAZYME

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Cinnagen	PHASE3
UCSF Benioff Children's Hospital Oakland	N/A
Children's Hospital & Research Center Oakland	N/A

See all ALDURAZYME clinical trials

Pharmacology for ALDURAZYME

Established Pharmacologic Class	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Chemical Structure	alpha-Glucosidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ALDURAZYME Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ALDURAZYME Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2019-04-29	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2017-04-14	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2018-12-15	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2020-03-27	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2020-02-25	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ALDURAZYME Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2036-12-20	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2036-08-10	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2036-06-14	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2034-03-11	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2038-12-19	Patent claims search

International Patents for ALDURAZYME

Country	Patent Number	Estimated Expiration
China	100462717
Japan	4470999
European Patent Office	1867985
Japan	4734498
China	1717418

ALDURAZYME (laronidase): Market dynamics and financial trajectory

Last updated: April 26, 2026

ALDURAZYME (laronidase) is a long-established ERT for mucopolysaccharidosis I (MPS I) that has entered a mature, value-reduction phase shaped by (1) enzyme competition, (2) channel and payor contracting dynamics, and (3) pipeline pressure from next-generation therapies. The commercial trajectory is characterized by declining growth, periodic revenue step-downs around pricing and mix, and continued reliance on contracted institutional uptake rather than broad expansion.

What is ALDURAZYME’s commercial foundation?

Drug and indication

• Brand: ALDURAZYME
• Generic/INN: laronidase (recombinant human α-L-iduronidase)
• Indication: MPS I (Hurler, Hurler-Scheie, Scheie syndromes)

Therapy model

• ALDURAZYME is an intravenous enzyme replacement therapy (ERT) requiring ongoing infusions.
• Long-duration chronic use drives “installed base” revenue but also increases payor pushback on unit economics over time.

Pricing and payer contracting implications

• As a chronic specialty biologic, ALDURAZYME’s revenue sensitivity is driven by:
  • Net price compression via rebates, managed-entry agreements, and reference pricing.
  • Site-of-care mix (hospital outpatient vs home infusion vs specialty pharmacies where allowed).
  • Patient retention and the pace of switches if competing ERTs or alternative modalities gain reimbursement traction.

How do market dynamics affect demand?

Competition and therapeutic switching

ALDURAZYME’s market is governed by rare-disease contracting norms, but competitive entry and prescriber preference still matter. The main dynamics typically include:

• Switching pressure when a competing product offers improved administration convenience, clinical endpoints, or economic terms.
• Prior authorization tightening as payors respond to high-cost specialty trends.
• Center-of-excellence concentration: even with rare diseases, procurement and formulary status can be decisive at major treatment centers.

Practical implication

• Growth is rarely “new patient-led” after the initial label adoption window; it becomes “contract-led” and “switch-led,” with revenue performance tied to net pricing and retention.

Patient pool economics for MPS I

MPS I is ultra-rare, so commercial outcomes depend on:

• Diagnosis rates (new ascertainment via genetic screening and newborn screening programs in certain geographies).
• Treatment eligibility (age, organ involvement, comorbidities).
• Treatment persistence on chronic IV therapy.

Practical implication

• Even without a full cure replacement, the addressable market is bounded, and incremental revenue depends on retention and reimbursement breadth.

Global reimbursement and access

ERTs for rare diseases are typically reimbursed through a mix of:

• National rare disease programs
• Hospital formularies
• Managed care specialty tiers

Practical implication

• Launch cadence and label expansions can bring step-ups, but the later phase tends to show flatter demand with recurring net price adjustments.

What is ALDURAZYME’s financial trajectory by phase?

1) Early scaling and institutional adoption

ALDURAZYME established revenue by converting a limited patient base into an ongoing, infusion-based treated population. This stage usually shows:

• Rapid uptake at specialty centers
• Incremental new patient starts
• Predominantly list-price-based revenue early on (before aggressive rebate structures mature)

2) Mature market with net price pressure

As the product matured, financial trajectory moved toward:

• Net revenue compression from payer rebates and contracting
• Revenue flattening as the treated pool saturated
• Increased emphasis on retention rather than expansion

This is characteristic of high-cost biologics in rare diseases, where commercial negotiations evolve toward value-based or budget-impact aligned terms.

3) Late-stage risk from next-generation options

The late-phase risk set for ALDURAZYME includes:

• Competitive biologic enzymes in the same space (or new presentations of existing platforms)
• Policy and payer shifts that favor lower administration burden or improved cost-effectiveness
• Potential cohort migration to other disease-modifying options if available and reimbursed

Practical implication

• Even if ALDURAZYME maintains share, revenue growth tends to trend to low or negative as net prices and mix shift.

Where does ALDURAZYME sit in the global biologics revenue landscape?

ALDURAZYME is an example of a legacy rare-disease biologic with a revenue base that behaves like a “chronic maintenance franchise,” not a growth franchise. For financial planning, the key levers are:

• Net price vs list price
• Reimbursement coverage continuity
• Site-of-care contracting
• Switching risk to alternative therapies

Revenue drivers and financial KPIs (what moves the needle)

Revenue lever	How it affects ALDURAZYME	Typical financial signal
Net price (rebates/discounts)	Chronic negotiating pressure	Revenue declines despite stable utilization
Treated patient count	Rare disease pool saturation	Flat starts and stable total infusions
Persistence (duration on therapy)	Loss from non-persistence reduces totals	Gradual revenue fade rather than abrupt step-down
Site of care and logistics	Contracting changes unit economics	Revenue/mix changes with stable volume
Formulary access	Managed care coverage tightening	Temporary step-downs after contracting refresh

What does the competitive environment imply for forward financial trajectory?

Base case pattern

• ALDURAZYME’s revenue trajectory is usually dominated by net price and contract renewals.
• Without a large-scale new indication or major expansion of reimbursed eligibility, the product sits in a mature revenue curve.

Downside pattern

• If payors reduce net coverage or tighten access criteria, the treated base shrinks.
• If a competing option gains formulary placement, switching can accelerate revenue erosion.

Upside pattern

• Diagnosis growth and eligibility expansion can raise treated volumes, but for MPS I these effects are typically slower than price-driven changes.

Key commercial takeaways for investors and R&D planners

1) ALDURAZYME revenue is “contracted continuity”

The financial trajectory is best modeled as continuity of a chronic cohort with periodic net price resets.

2) The main variable is not clinical penetration

For mature ERTs in ultra-rare diseases, market share changes are frequently driven by:

• payer contracting
• site-of-care economics
• formulary placement

3) Pipeline and next-generation pressure drives caution on long-term growth

Even when ALDURAZYME remains clinically used, the economic and access landscape tends to limit net growth.

---

Key Takeaways

• ALDURAZYME is a mature, chronic ERT whose revenue behavior is dominated by net price compression, contracting outcomes, and persistence of a fixed rare-disease cohort.
• Market dynamics are payer-led: managed entry, rebate structures, and site-of-care contracting typically drive revenue step-downs or flattening.
• Forward financial upside is limited unless there is reimbursement expansion or meaningful cohort growth; downside risk comes from switching and tighter access.

FAQs

1. What economic driver most directly affects ALDURAZYME revenue in mature markets?
   Net price from rebates and contracting, plus formulary and site-of-care economics.

2. Does ALDURAZYME growth depend primarily on new patient launches?
   In the mature phase, growth depends more on retention and contracted access than on new patient starts.

3. How does competition typically impact ALDURAZYME’s revenue trajectory?
   Through formulary placement and switching risk that can reduce persistence or volume over time.

4. What commercial KPIs best track ALDURAZYME’s financial performance?
   Treated patient count, persistence, net price, and site-of-care mix.

5. What is the most common pattern for legacy rare-disease biologics?
   Flattening or decline driven by net price resets and access tightening, even if clinical use remains steady.

---

References

[1] U.S. Food and Drug Administration. ALDURAZYME (laronidase) prescribing information. FDA label.
[2] European Medicines Agency (EMA). Aldurazyme EPAR (European public assessment report). EMA.
[3] Orphanet. Mucopolysaccharidosis type I (MPS I): disease overview and treatment context. Orphanet.